Literature DB >> 24402945

Towards a unified model of RAF inhibitor resistance.

David B Solit1, Neal Rosen.   

Abstract

ATP-competitive RAF inhibitors elicit profound but often temporary antitumor responses in patients with BRAF-mutant melanoma. Analysis of tumor samples collected at the time of disease progression indicates that alterations within the extracellular signal-regulated kinase (ERK) pathway that result in reactivation of ERK signaling are present in most patients. Mutations in the phosphoinositide 3-kinase/AKT pathway that enhance the adaptive response to RAF inhibitors also contribute to RAF inhibitor resistance in a subset of patients.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24402945      PMCID： PMC4986142          DOI： 10.1158/2159-8290.CD-13-0961

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  18 in total

1.  BRAF mutation predicts sensitivity to MEK inhibition.

Authors:  David B Solit; Levi A Garraway; Christine A Pratilas; Ayana Sawai; Gad Getz; Andrea Basso; Qing Ye; Jose M Lobo; Yuhong She; Iman Osman; Todd R Golub; Judith Sebolt-Leopold; William R Sellers; Neal Rosen
Journal:  Nature       Date:  2005-11-06       Impact factor: 49.962

2.  Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

Authors:  Nikhil Wagle; Caroline Emery; Michael F Berger; Matthew J Davis; Allison Sawyer; Panisa Pochanard; Sarah M Kehoe; Cory M Johannessen; Laura E Macconaill; William C Hahn; Matthew Meyerson; Levi A Garraway
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

3.  A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.

Authors:  Steven R Whittaker; Jean-Philippe Theurillat; Eliezer Van Allen; Nikhil Wagle; Jessica Hsiao; Glenn S Cowley; Dirk Schadendorf; David E Root; Levi A Garraway
Journal:  Cancer Discov       Date:  2013-01-03       Impact factor: 39.397

4.  MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.

Authors:  Nikhil Wagle; Eliezer M Van Allen; Daniel J Treacy; Dennie T Frederick; Zachary A Cooper; Amaro Taylor-Weiner; Mara Rosenberg; Eva M Goetz; Ryan J Sullivan; Deborah N Farlow; Dennis C Friedrich; Kristin Anderka; Danielle Perrin; Cory M Johannessen; Aaron McKenna; Kristian Cibulskis; Gregory Kryukov; Eran Hodis; Donald P Lawrence; Sheila Fisher; Gad Getz; Stacey B Gabriel; Scott L Carter; Keith T Flaherty; Jennifer A Wargo; Levi A Garraway
Journal:  Cancer Discov       Date:  2013-11-21       Impact factor: 39.397

5.  Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.

Authors:  Meghna Das Thakur; Fernando Salangsang; Allison S Landman; William R Sellers; Nancy K Pryer; Mitchell P Levesque; Reinhard Dummer; Martin McMahon; Darrin D Stuart
Journal:  Nature       Date:  2013-01-09       Impact factor: 49.962

6.  Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.

Authors:  Emanuela Romano; Sylvain Pradervand; Alexandra Paillusson; Johann Weber; Keith Harshman; Katja Muehlethaler; Daniel Speiser; Solange Peters; Donata Rimoldi; Olivier Michielin
Journal:  Clin Cancer Res       Date:  2013-08-15       Impact factor: 12.531

7.  Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF.

Authors:  F Xing; Y Persaud; C A Pratilas; B S Taylor; M Janakiraman; Q-B She; H Gallardo; C Liu; T Merghoub; B Hefter; I Dolgalev; A Viale; A Heguy; E De Stanchina; D Cobrinik; G Bollag; J Wolchok; A Houghton; D B Solit
Journal:  Oncogene       Date:  2011-07-04       Impact factor: 9.867

8.  Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.

Authors:  Hubing Shi; Gatien Moriceau; Xiangju Kong; Mi-Kyung Lee; Hane Lee; Richard C Koya; Charles Ng; Thinle Chodon; Richard A Scolyer; Kimberly B Dahlman; Jeffrey A Sosman; Richard F Kefford; Georgina V Long; Stanley F Nelson; Antoni Ribas; Roger S Lo
Journal:  Nat Commun       Date:  2012-03-06       Impact factor: 14.919

9.  RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

Authors:  Poulikos I Poulikakos; Chao Zhang; Gideon Bollag; Kevan M Shokat; Neal Rosen
Journal:  Nature       Date:  2010-03-18       Impact factor: 49.962

10.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).

Authors:  Poulikos I Poulikakos; Yogindra Persaud; Manickam Janakiraman; Xiangju Kong; Charles Ng; Gatien Moriceau; Hubing Shi; Mohammad Atefi; Bjoern Titz; May Tal Gabay; Maayan Salton; Kimberly B Dahlman; Madhavi Tadi; Jennifer A Wargo; Keith T Flaherty; Mark C Kelley; Tom Misteli; Paul B Chapman; Jeffrey A Sosman; Thomas G Graeber; Antoni Ribas; Roger S Lo; Neal Rosen; David B Solit
Journal:  Nature       Date:  2011-11-23       Impact factor: 49.962
View more
  23 in total

Review 1.  Mapping the Pathways of Resistance to Targeted Therapies.

Authors:  Kris C Wood
Journal:  Cancer Res       Date:  2015-09-21       Impact factor: 12.701

Review 2.  Targeting mitochondrial metabolism by inhibiting autophagy in BRAF-driven cancers.

Authors:  Anne M Strohecker; Eileen White
Journal:  Cancer Discov       Date:  2014-05-23       Impact factor: 39.397

Review 3.  The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression.

Authors:  Asaf Shilo; Zahava Siegfried; Rotem Karni
Journal:  Mol Cell Oncol       Date:  2014-12-01

4.  The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function.

Authors:  Lixin Wan; Ming Chen; Juxiang Cao; Xiangpeng Dai; Qing Yin; Jinfang Zhang; Su-Jung Song; Ying Lu; Jing Liu; Hiroyuki Inuzuka; Jesse M Katon; Kelsey Berry; Jacqueline Fung; Christopher Ng; Pengda Liu; Min Sup Song; Lian Xue; Roderick T Bronson; Marc W Kirschner; Rutao Cui; Pier Paolo Pandolfi; Wenyi Wei
Journal:  Cancer Discov       Date:  2017-02-07       Impact factor: 39.397

5.  Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF.

Authors:  Amber Y Gunderwala; Anushri A Nimbvikar; Nicholas J Cope; Zhijun Li; Zhihong Wang
Journal:  ACS Chem Biol       Date:  2019-06-17       Impact factor: 5.100

6.  Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group.

Authors:  Keith C Bible; Gilbert J Cote; Michael J Demeure; Rossella Elisei; Sissy Jhiang; Matthew D Ringel
Journal:  J Clin Endocrinol Metab       Date:  2015-09-29       Impact factor: 5.958

7.  Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.

Authors:  Bingying Zhou; Daniel A Ritt; Deborah K Morrison; Channing J Der; Adrienne D Cox
Journal:  J Biol Chem       Date:  2016-05-17       Impact factor: 5.157

8.  Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors.

Authors:  Donita C Brady; Matthew S Crowe; Danielle N Greenberg; Christopher M Counter
Journal:  Cancer Res       Date:  2017-10-06       Impact factor: 12.701

Review 9.  Directly targeting transcriptional dysregulation in cancer.

Authors:  Thomas J Gonda; Robert G Ramsay
Journal:  Nat Rev Cancer       Date:  2015-11       Impact factor: 60.716

10.  Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAFV600E-Driven Melanoma.

Authors:  Ye-Jin Kim; Tiffany Tsang; Gray R Anderson; Jessica M Posimo; Donita C Brady
Journal:  Cancer Res       Date:  2020-01-31       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.